Literature DB >> 25661249

Protective effects of diltiazem against vascular endothelial cell injury induced by angiotensin-II and hypoxia.

Minggao Li1, Jing Li, Guo Meng, Xin Liu.   

Abstract

To provide pharmacological data for future clinical studies, this study investigated the protective effects of diltiazem on vascular endothelial cell (VEC) injury induced by angiotensin-II (AngII), hypoxia, and a combination of both treatments. The concentration of intracellular free calcium and the mitochondrial membrane potential in VEC were assessed as indicators of cell injury. An in vivo hypoxic animal model was used to test the protective effect of diltiazem on vascular endothelial tissues. Our study showed that AngII and hypoxia decreased the mitochondrial membrane potential in VEC, which was significantly inhibited by diltiazem. Diltiazem protected against VEC injury induced by the increased concentration of intracellular free calcium, which was associated with AngII and hypoxia. Diltiazem reduced the apoptosis of rat VEC under a sustained hypoxic condition. In addition, it reduced AngII and endothelin I levels in rat vascular endothelial tissues. Our study confirmed that AngII and hypoxia induced VEC injury by regulating the levels of mitochondrial membrane potential and intracellular free calcium. Diltiazem, a calcium channel blocker, protected VEC from AngII- and hypoxia-induced injury.
© 2015 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  angiotensin-II (AngII); diltiazem; hypoxia; vascular endothelial cells

Mesh:

Substances:

Year:  2015        PMID: 25661249     DOI: 10.1111/1440-1681.12371

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  1 in total

1.  The Effect of Diltiazem on Microcirculation of Transplanted Tissue Flaps: Experimental Study on Rabbits.

Authors:  Mahammad M Davudov; Jamal Musayev; Adalat Hasanov; Hamid Reza Fathi
Journal:  World J Plast Surg       Date:  2021-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.